In short
Clinical trials are investigating RO7837195 in people with moderately to severely active ulcerative colitis. The studies aim to evaluate efficacy, safety, and how the body handles RO7837195, with a focus on inducing remission compared with placebo.
Key points
- RO7837195 is being studied in a Phase 2 clinical trial for people with moderately to severely active ulcerative colitis. The study is designed to compare RO7837195 with placebo and to see whether it can help induce remission. Researchers are also evaluating safety and how the body handles RO7837195. The planned enrollment is 224 participants. The main outcome is clinical remission at Week 12, using symptom scores and endoscopy findings.
Trial overview
The available study is an interventional study, which means participants receive a study treatment so researchers can compare outcomes. It is evaluating RO7837195 in people with moderately to severely active ulcerative colitis, and the study is authorised.
The trial aims to assess efficacy, safety, and what the body does to RO7837195, which refers to how the treatment is processed in the body. The brief summary says the study is designed to compare RO7837195 with placebo to see whether it can induce remission.
Who can participate
The target population is participants with moderately to severely active ulcerative colitis (UC). The source data do not provide more detailed entry rules, such as age limits or prior treatments.
The planned enrollment is 224 participants, which means the study is designed to include that number of people.
What the study measures
The main endpoint is clinical remission at Week 12. An endpoint is the main result researchers use to judge whether the study treatment has the desired effect.
In this trial, clinical remission is defined using the modified Mayo score (mMS) of 2 or less, with specific limits for stool frequency, rectal bleeding, and endoscopy findings. In simple terms, the study is checking whether bowel symptoms and bowel lining appearance improve enough to meet a strict remission score.
Study design and phase
This is a Phase 2 trial. Phase 2 studies usually focus on whether a treatment may work while continuing to monitor safety.
The study includes RO7837195 given by subcutaneous use, which means it is given under the skin, and it also includes a placebo comparison. The source also lists RO7837195 as a drug intervention in the study.
Key medical terms
Ulcerative colitis is a long-term inflammatory disease of the colon and rectum that can cause diarrhea, bleeding, and urgency. Remission means the disease signs are very low or absent.
Endoscopy is a test that lets doctors look inside the bowel with a camera. In this study, endoscopy is part of the remission definition because it helps show whether the bowel lining has improved.
Placebo is a look-alike treatment used for comparison in research, so scientists can see whether the study drug has a real effect. Mayo subscores are parts of a scoring system used to measure ulcerative colitis activity.